{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:49:12Z","timestamp":1789602552560,"version":"build-2803163510"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Traditional cystic fibrosis (CF) care had been focused on early intervention and symptom mitigation. With the advent of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy (HEMT), in particular, the approval of elexacaftor\/tezacaftor\/ivacaftor in 2019, there has been a dramatic improvement in outcomes in CF. The purpose of this article is to review the benefits, limitations, and impact of HEMT as well as discuss the new implications, challenges, and hope that modulators bring to people with CF (pwCF).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>HEMT has demonstrated sustained improvement in lung function, nutrition, quality of life, and survival for over 90% of pwCF. As HEMT has delivered such promise, there is a small but significant portion of pwCF who do not benefit from HEMT due to ineligible mutations, intolerance, or lack of accessibility to modulators.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>HEMT has significantly improved outcomes, but continued research is needed to understand the new challenges and implications the era of HEMT will bring, as well as how to provide equitable care to those who are unable to benefit from HEMT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001338","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T11:02:27Z","timestamp":1709031747000},"page":"290-295","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind"],"prefix":"10.1097","volume":"36","author":[{"given":"Stanford W.","family":"Chun","sequence":"first","affiliation":[{"name":"Division of Pediatric Pulmonology & Sleep Medicine, Department of Pediatrics, Children's Hospital of Los Angeles, Keck School of Medicine at University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya E.","family":"Somers","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease & Geographic Medicine, Department of Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Burgener","sequence":"additional","affiliation":[{"name":"Division of Pediatric Pulmonology & Sleep Medicine, Department of Pediatrics, Children's Hospital of Los Angeles, Keck School of Medicine at University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"issue":"(Suppl 1)","key":"R1-20250730","first-page":"S5","article-title":"Increasing life expectancy in cystic fibrosis: advances and challenges","volume":"57","author":"McBennett","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcf.2020.11.008","article-title":"Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation","volume":"20","author":"Guimbellot","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in children aged \u2a7e6 years with cystic fibrosis and at least one F508del allele: a phase 3, open-label clinical trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/children10020252","article-title":"Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: a cohort study and evaluation of the effect of CFTR modulators","volume":"10","author":"Francalanci","year":"2023","journal-title":"Children"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"852551","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of elexacaftor\/tezacaftor\/ivacaftor combination on glucose tolerance in young people with cystic fibrosis \u2013 an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","article-title":"Nonrespiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Fajac","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R16-20250730","article-title":"Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations","author":"Sellers","year":"2023","journal-title":"Hepatology"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/cpt.2585","article-title":"Physiologically-based pharmacokinetic-led guidance for patients with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor with nirmatrelvir-ritonavir for the treatment of COVID-19","volume":"111","author":"Hong","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ccm.2022.06.014","article-title":"Management of mental health in cystic fibrosis","volume":"43","author":"Bathgate","year":"2022","journal-title":"Clin Chest Med"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2021","journal-title":"J Clin Med"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jcf.2023.01.015","article-title":"Suicide attempts in adolescents with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"22","author":"Arslan","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"17534666221144211","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R23-20250730","first-page":"6708865","article-title":"Global burden of anxiety and depression among cystic fibrosis patient: systematic review and meta-analysis","volume":"2021","author":"Guta","year":"2021","journal-title":"Int J Chronic Dis"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"00127","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"1156621","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front Pharmacol"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ppul.26400","article-title":"National integration of mental health screening and treatment into specialized care for cystic fibrosis: what predicts success?","volume":"58","author":"Quittner","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, noninferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/mrm.28947","article-title":"Defect distribution index: a novel metric for functional lung MRI in cystic fibrosis","volume":"86","author":"Valk","year":"2021","journal-title":"Magn Reson Med"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.202102-0278OC","article-title":"Magnetic resonance imaging detects progression of lung disease and impact of newborn screening in preschool children with cystic fibrosis","volume":"204","author":"Stahl","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12890-022-01903-5","article-title":"Lung clearance index to characterize clinical phenotypes of children and adolescents with cystic fibrosis","volume":"22","author":"Gambazza","year":"2022","journal-title":"BMC Pulm Med"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1513\/AnnalsATS.202303-245OC","article-title":"A pilot randomized clinical trial of pediatric cystic fibrosis pulmonary exacerbations treatment strategies","volume":"20","author":"Sanders","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O\u2019Connor","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/14647273.2022.2161427","article-title":"The role of CFTR channel in female infertility","volume":"26","author":"Habibullah","year":"2023","journal-title":"Hum Fertil"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"e001289","DOI":"10.1136\/bmjresp-2022-001289","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.3390\/jcm9092706","article-title":"CFTR modulators: impact on fertility, pregnancy, and lactation in women with cystic fibrosis","volume":"9","author":"Taylor-Cousar","year":"2020","journal-title":"J Clin Med"},{"issue":"(Suppl 1)","key":"R38-20250730","first-page":"25","article-title":"Potential impact on fertility of new systemic therapies for cystic fibrosis","volume":"16","author":"Jones","year":"2015","journal-title":"Paediatr Respir Rev"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jcf.2021.07.019","article-title":"Pregnancy in cystic fibrosis: Review of the literature and expert recommendations","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"220005","DOI":"10.1183\/20734735.0005-2022","article-title":"Management of pregnancy in cystic fibrosis","volume":"18","author":"Montemayor","year":"2022","journal-title":"Breathe"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/ppul.26706","article-title":"Use of CFTR modulators in special populations, part 1: pregnancy and lactation","volume":"58","author":"Elijah","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/L23-0112","article-title":"Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy","volume":"176","author":"Blumenfeld","year":"2023","journal-title":"Ann Intern Med"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/jcm12041468","article-title":"Pregnancy in cystic fibrosis\u2014past, present, and future","volume":"12","author":"Gur","year":"2023","journal-title":"J Clin Med"},{"key":"R49-20250730","first-page":"3","article-title":"Cystic fibrosis-related diabetes: clinical approach and knowledge gaps","volume":"46","author":"Prentice","year":"2023","journal-title":"Paediatr Respir Rev"},{"key":"R50-20250730","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0042-1758734","article-title":"Beyond the lungs-emerging challenges in adult cystic fibrosis care","volume":"44","author":"Mulrennan","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"issue":"(Suppl 1)","key":"R51-20250730","first-page":"S113","article-title":"Looking toward the future: approaching care of the aging CF patient","volume":"57","author":"Sala","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"106878","DOI":"10.1016\/j.rmed.2022.106878","article-title":"Who are the 10%? \u2013 non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies","volume":"199","author":"Desai","year":"2022","journal-title":"Respir Med"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"R54-20250730","first-page":"35","article-title":"Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis","volume":"42","author":"McGarry","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"R55-20250730","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R56-20250730","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.ymthe.2023.03.004","article-title":"Functional restoration of a CFTR splicing mutation through RNA delivery of CRISPR adenine base editor","volume":"31","author":"Amistadi","year":"2023","journal-title":"Mol Ther"},{"key":"R57-20250730","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/life13091835","article-title":"Advances in the cystic fibrosis drug development pipeline","volume":"13","author":"Esposito","year":"2023","journal-title":"Life"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:03:28Z","timestamp":1753898608000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001338","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}